Literature DB >> 23519178

Tuberous sclerosis and fulminant lupus in a young woman.

Namrata Singh1, Mark Birkenbach, Tiffany Caza, Andras Perl, Philip L Cohen.   

Abstract

Tuberous sclerosis is an autosomal dominant disorder characterized by involvement of skin, nervous system, kidneys, and lungs. It results from mutations in 1 of 2 genes: TSC1 (encoding hamartin) or TSC2 (encoding tuberin), leading to dysregulation and activation of the mammalian target of rapamycin (mTOR) pathway. Constitutive activation of mTOR signaling has recently been reported in systemic lupus erythematosus (SLE), and inhibition of this pathway may benefit patients with SLE nephritis. We report a case of a young woman with tuberous sclerosis who developed fulminant SLE, with lower extremity edema, massive proteinuria, and class IV lupus glomerulonephritis. She died despite treatment with high-dose steroids, plasmapheresis, and cyclophosphamide. Although there are no prior reports of coexistence of these 2 rare diseases, this case is of considerable interest because of the possibility that activation of mTOR by the TSC mutations may have led to activation of the immune system and the development of unusually severe SLE.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519178      PMCID: PMC4034128          DOI: 10.1097/RHU.0b013e318289c033

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  13 in total

Review 1.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.

Authors:  S N Sehgal
Journal:  Clin Biochem       Date:  1998-07       Impact factor: 3.281

2.  The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.

Authors:  Kostas Stylianou; Ioannis Petrakis; Vasiliki Mavroeidi; Stavros Stratakis; Eleftheria Vardaki; Kostas Perakis; Spyros Stratigis; Andreas Passam; Eva Papadogiorgaki; Kostas Giannakakis; Lydia Nakopoulou; Eugene Daphnis
Journal:  Nephrol Dial Transplant       Date:  2010-08-13       Impact factor: 5.992

3.  PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.

Authors:  Domingo F Barber; Almira Bartolomé; Carmen Hernandez; Juana M Flores; Clara Redondo; Cristina Fernandez-Arias; Montserrat Camps; Thomas Rückle; Matthias K Schwarz; Santiago Rodríguez; Carlos Martinez-A; Dimitrios Balomenos; Christian Rommel; Ana C Carrera
Journal:  Nat Med       Date:  2005-08-28       Impact factor: 53.440

4.  Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.

Authors:  Sing Leung Lui; Ryan Tsang; Kwok Wah Chan; Florence Zhang; Sidney Tam; Susan Yung; Tak Mao Chan
Journal:  Nephrol Dial Transplant       Date:  2008-04-29       Impact factor: 5.992

5.  Apoptosis and mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus.

Authors:  Andras Perl; Gyorgy Nagy; Peter Gergely; Ferenc Puskas; Yueming Qian; Katalin Banki
Journal:  Methods Mol Med       Date:  2004

6.  Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus.

Authors:  L M Warner; L M Adams; S N Sehgal
Journal:  Arthritis Rheum       Date:  1994-02

7.  Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation.

Authors:  David R Fernandez; Tiffany Telarico; Eduardo Bonilla; Qing Li; Sanjay Banerjee; Frank A Middleton; Paul E Phillips; Mary K Crow; Stefanie Oess; Werner Muller-Esterl; Andras Perl
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

8.  Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway.

Authors:  Weiping Cao; Santhakumar Manicassamy; Hua Tang; Sudhir Pai Kasturi; Ali Pirani; Niren Murthy; Bali Pulendran
Journal:  Nat Immunol       Date:  2008-08-31       Impact factor: 25.606

9.  Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.

Authors:  David Fernandez; Eduardo Bonilla; Naureen Mirza; Brian Niland; Andras Perl
Journal:  Arthritis Rheum       Date:  2006-09

10.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

Authors:  Manuela Battaglia; Angela Stabilini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

View more
  14 in total

Review 1.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

Review 2.  Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.

Authors:  Mindy S Lo; George C Tsokos
Journal:  Curr Opin Rheumatol       Date:  2018-03       Impact factor: 5.006

3.  A case of systemic lupus erythematosus with multiple nodules in the bilateral lungs and vertebrae.

Authors:  Takuma Tsuzuki Wada; Kojiro Sato; Toshihide Mimura
Journal:  Eur J Rheumatol       Date:  2015-08-21

Review 4.  Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.

Authors:  Zachary Oaks; Thomas Winans; Nick Huang; Katalin Banki; Andras Perl
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

Review 5.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

6.  Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/RAB4 expression and mTOR activation.

Authors:  Aparna Godavarthy; Ryan Kelly; John Jimah; Miguel Beckford; Tiffany Caza; David Fernandez; Nick Huang; Manuel Duarte; Joshua Lewis; Hind J Fadel; Eric M Poeschla; Katalin Banki; Andras Perl
Journal:  JCI Insight       Date:  2020-01-16

Review 7.  Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis.

Authors:  Tiffany Caza; Chathura Wijewardena; Laith Al-Rabadi; Andras Perl
Journal:  Transl Res       Date:  2022-03-12       Impact factor: 10.171

Review 8.  T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy.

Authors:  Amir Sharabi; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2020-01-16       Impact factor: 20.543

9.  Tsc1 expression by dendritic cells is required to preserve T-cell homeostasis and response.

Authors:  Yuechen Luo; Wenwen Li; Gang Yu; Juan Yu; Ling Han; Ting Xue; Zhina Sun; Song Chen; Chunming Fang; Chunxiao Zhao; Qing Niu; Fei Yang; Zhongchao Han; Tao Cheng; Yun Zeng; Fang Liao; Guogang Xu; Xiaoming Feng
Journal:  Cell Death Dis       Date:  2017-01-12       Impact factor: 8.469

Review 10.  Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.

Authors:  Takayuki Katsuyama; George C Tsokos; Vaishali R Moulton
Journal:  Front Immunol       Date:  2018-05-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.